Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...

Please provide your email address to receive an email when new articles are posted on . Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection ...

On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for the label to ...

Mylan Pharmaceuticals recalled one batch of Insulin Glargine Injection, 100 units/mL (U-100), 3 mL prefilled pens, which are sold in cartons of five. Some pens might be missing their labels. In ...

TRENTON, N.J. — A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit over ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector ...

Californians with diabetes will soon have access to a low-cost insulin pen as part of a new state initiative announced today, October 16, by Gov. Gavin Newsom.Beginning Jan. 1, 2026, CalRx-branded ...